A cross‐national cost‐effectiveness analysis of brivaracetam focusing on psychiatric and behavioral adverse effects

Documenti analoghi

• Treatment with brivaracetam has no apparent long‐term effects on body weight in pediatric patients with epilepsy
  di: Florin I. Floricel, et al.
  Pubblicazione: (2024)
• A multicenter, cross‐sectional analysis to assess the safety and usage pattern of brivaracetam in the management of partial‐onset seizure with BAEs—BREEZE study: A post‐hoc analysis
  di: Arvind Sharma, et al.
  Pubblicazione: (2024)
• BRIVA‐ONE study: 12‐month outcomes of brivaracetam monotherapy in clinical practice
  di: Vicente Villanueva, et al.
  Pubblicazione: (2024)
• Prevalence and associated factors of psychiatric comorbidities in epilepsy in the Casablanca–Settat region of Morocco: A cross‐sectional study
  di: El Bachir Hajji, et al.
  Pubblicazione: (2024)
• The cenobamate KORK study—A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add‐on lacosamide, perampanel, and brivaracetam
  di: Bernhard J. Steinhoff, et al.
  Pubblicazione: (2024)